GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kidswell Bio 4584.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

140

+2.19%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥6.59bn

FY2017FY2026

Net income

−¥414.0m

FY2017FY2026

Free cash flow

−¥1.11bn

FY2017FY2026

Shareholders' equity

¥1.65bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥6.59bn¥5.08bn¥2.43bn¥2.78bn¥1.57bn¥996.5m¥1.08bn¥1.02bn¥1.06bn¥1.09bn
Research and development¥1.12bn¥767.9m¥1.45bn¥1.22bn¥903.1m¥963.9m¥898.0m¥945.2m¥1.11bn¥1.43bn
Operating income−¥358.7m¥115.4m−¥1.38bn−¥619.6m−¥651.1m−¥979.5m−¥7.31bn−¥805.2m−¥913.5m−¥1.23bn
Net income−¥414.0m−¥21.1m−¥1.42bn−¥657.4m−¥550.9m−¥1.00bn−¥7.32bn−¥856.3m−¥904.6m−¥1.22bn
Diluted earnings per share-8.16-0.43-34.97-17.61-17.40-31.86-251.77-30.97-46.08-64.38

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥6.09bn¥7.01bn¥5.09bn¥3.89bn¥3.47bn¥3.93bn¥3.59bn¥3.15bn¥3.03bn¥3.71bn
Cash and short-term investments¥3.29bn¥3.00bn¥2.23bn¥1.07bn¥1.16bn¥1.46bn¥2.03bn¥2.01bn¥1.89bn¥2.38bn
Total liabilities¥4.43bn¥5.60bn¥4.25bn¥2.66bn¥1.77bn¥2.32bn¥2.10bn¥420.1m¥421.1m¥206.0m
Debt¥2.55bn¥1.84bn¥2.58bn¥1.95bn¥700.0m¥1.10bn¥1.23bn———
Shareholders' equity¥1.65bn¥1.41bn¥831.5m¥1.23bn¥1.70bn¥1.61bn¥1.49bn¥2.73bn¥2.60bn¥3.50bn
Shares outstanding51m50m41m37m32m31m29m28m20m19m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−¥1.09bn¥936.7m−¥453.6m−¥1.42bn−¥1.17bn−¥1.27bn−¥1.3m−¥860.3m−¥438.4m−¥1.76bn
Capital spending−¥17.6m−¥6.4m−¥453.6m−¥1.42bn−¥160,000−¥3.3m−¥1.9m−¥1.0m−¥252,000−¥252,000
Free cash flow−¥1.11bn¥930.3m−¥907.3m−¥2.84bn−¥1.17bn−¥1.27bn−¥3.3m−¥861.3m−¥438.6m−¥1.76bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥1.27bn¥1.57bn¥1.74bn¥1.56bn¥1.72bn¥2.05bn¥1.29bn¥1.27bn
Operating income¥216.5m−¥222.6m−¥131.3m¥30.7m¥184.7m¥165.8m¥124.6m−¥103.6m
Net income¥197.9m−¥271.2m−¥203.4m−¥96.5m¥157.1m¥166.6m¥54.0m−¥65.1m
Diluted earnings per share3.90-5.34-4.10-1.953.173.361.33-1.60
Total assets¥6.13bn¥6.09bn¥6.32bn¥5.82bn¥6.58bn¥7.01bn¥4.57bn¥4.65bn
Cash and short-term investments¥3.23bn¥3.29bn¥3.78bn¥1.54bn¥2.84bn¥3.00bn¥1.32bn¥1.70bn
Debt¥425.0m¥2.55bn¥300.0m¥1.13bn¥657.0m¥1.84bn¥547.0m¥2.13bn
Shareholders' equity¥1.84bn¥1.65bn¥1.93bn¥2.19bn¥2.05bn¥1.41bn¥1.05bn¥857.2m

Financial ratios

Data as of 2 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021
Operating margin-5.4%2.3%-56.7%-22.3%-41.5%-98.3%
Net margin-6.3%-0.4%-58.5%-23.7%-35.1%-100.5%
Return on equity-25.0%-1.5%-171.0%-53.3%-32.3%-62.2%
Return on assets-6.8%-0.3%-28.0%-16.9%-15.9%-25.5%
Free cash flow yield-13.1%11.7%0.0%0.0%-22.8%-24.8%
Revenue growth29.7%109.0%-12.4%76.9%57.5%-7.5%
Earnings growth1858.3%-98.5%116.3%19.3%-45.0%-86.3%
Current ratio2.72x1.55x2.07x3.50x2.97x3.00x
Debt to equity1.54x1.30x3.10x1.58x0.41x0.68x
Equity ratio27.2%20.1%16.3%31.7%49.1%40.9%
Interest coverage-7.31x2.71x-35.57x-17.79x-42.12x-62.44x
R&D as a share of sales17.0%15.1%59.8%43.8%57.5%96.7%
Buybacks as a share of market value-2.3%-22.0%-8.9%-17.9%-0.7%-8.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue33.4%45.9%19.0%
Operating income-16.7%-18.2%-7.9%
Net income-14.3%-16.2%-6.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-2.1%-13.3%-19.9%-60.2%
Net margin-3.7%-14.9%-20.9%-61.0%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-17.9-476.3-3.1-7.6-15.3-15.5-2.0-33.0-17.0-21.6
Price to sales1.12.01.81.85.415.613.427.714.524.3

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 27 Jun 2018
  • 2-for-1 split · 28 Sept 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.